These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

598 related items for PubMed ID: 19337535

  • 1. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N.
    Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.
    Gupta R, Walunj SS, Tokala RK, Parsa KV, Singh SK, Pal M.
    Curr Drug Targets; 2009 Jan; 10(1):71-87. PubMed ID: 19149538
    [Abstract] [Full Text] [Related]

  • 6. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
    Bolli G, Dotta F, Colin L, Minic B, Goodman M.
    Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects.
    Elhini SH, Hussien AK, Omran AAE, Elsayed AA, Saeed H.
    Clin Exp Pharmacol Physiol; 2021 Dec; 48(12):1589-1602. PubMed ID: 34333803
    [Abstract] [Full Text] [Related]

  • 8. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.
    Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C.
    Vasc Health Risk Manag; 2008 Dec; 4(4):753-68. PubMed ID: 19065993
    [Abstract] [Full Text] [Related]

  • 9. DPP-4 inhibitors.
    Ahrén B.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):517-33. PubMed ID: 18054733
    [Abstract] [Full Text] [Related]

  • 10. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
    Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S.
    Diabetes Obes Metab; 2007 Mar; 9(2):166-74. PubMed ID: 17300592
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C, Toyama T, Oshima M, Jun M, Chin KL, Hawley CM, Zoungas S.
    Cochrane Database Syst Rev; 2020 Jul 30; 8(8):CD009966. PubMed ID: 32803882
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. DPP-4 inhibitors in clinical practice.
    Palalau AI, Tahrani AA, Piya MK, Barnett AH.
    Postgrad Med; 2009 Nov 30; 121(6):70-100. PubMed ID: 19940419
    [Abstract] [Full Text] [Related]

  • 15. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
    Scheen AJ.
    Diabetes Metab; 2012 Apr 30; 38(2):89-101. PubMed ID: 22197148
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
    Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL.
    Cochrane Database Syst Rev; 2008 Apr 16; 2008(2):CD006739. PubMed ID: 18425967
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.